Prostate cancer PET bioprobes: Synthesis of [18 F]-radiolabeled hydroxyflutamide derivatives

…, E Golan, I Leibovitch, M Gutman, E Even-Sapir…

Index: Jacobson, Orit; Bechor, Yossi; Icar, Avi; Novak, Nurit; Birman, Atalia; Marom, Hanit; Fadeeva, Ludmila; Golan, Elizabeth; Leibovitch, Ilan; Gutman, Mordechai; Even-Sapir, Einat; Chisin, Roland; Gozin, Michael; Mishani, Eyal Bioorganic and Medicinal Chemistry, 2005 , vol. 13, # 22 p. 6195 - 6205

Full Text: HTML

Citation Number: 28

Abstract

Approximately 80–90% of prostate cancers are androgen dependent at initial diagnosis. The androgen receptor (AR) is present in most advanced prostate cancer specimens and is believed to have a critical role in its development. Today, treatment of prostate cancer is done by inhibition of AR using antiandrogens such as flutamide (pro-drug of hydroxyflutamide), nilutamide, and bicalutamide. However, there is currently no ...